Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial

This trial is testing whether canakinumab — an anti-inflammatory drug — can prevent lung cancer in people at high risk. Specifically, researchers are studying people who have suspicious but undiagnosed lung nodules (small spots on the lung detected by CT scans) or who have had recent lung cancer surgery. Inflammation is thought to play a role in cancer development, and this drug blocks a key inflammatory protein. **You may be eligible if...** - You have had persistent lung nodules detected on at least two CT scans at least 3 months apart with no signs of shrinking, OR - You have recently had surgery to remove early-stage non-small cell lung cancer - You have no current lung cancer diagnosis - You are willing to give written consent **You may NOT be eligible if...** - You have an active lung cancer diagnosis - You have conditions that make immunotherapy drugs unsafe - You do not meet other health criteria defined in the protocol Talk to your doctor to see if this trial is right for you.